FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an "unfair" assessment process for NHS drug approval. At such a critical moment in ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

AstraZeneca and Daiichi Sankyo are also exploring earlier and even wider use of Enhertu. For one thing, because Enhertu also showed remarkable data in the lower expressers within the HER2-low ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY ...

Enhertu (T-DXd; fam-trastuzumab deruxtecan-nxki) reduced deterioration in physical and role functioning (ability to perform tasks) and pain compared with treatment of physician’s choice (TPC) in ...

Enhertu’s developers, AstraZeneca and Daiichi Sankyo, said in April the trial succeeded, but didn’t provide specifics. Trial data revealed at ASCO show Enhertu met its main objective by ...

Enhertu bears a list price of £1,455 per vial, and AZ and Daiichi have offered a confidential discount, which already applies to the drug’s use in previously treated HER2-positive breast cancer.

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY ...

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 ...

About ENHERTU. ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, ENHERTU is the ...

TOKYO & BASKING RIDGE, N.J., May 31, 2025--ENHERTU Reduced Risk of Death by 30% as 2L Therapy in Patients w/HER2+ Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial ...